

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

In accordance with the duty of disclosure under 37 C.F.R. §1.56, applicants direct the Examiner's attention to the following items, which are listed on the substitute Form PTO-1449 attached hereto as **Exhibit A**. Copies of items 1-15 are attached hereto as **Exhibits 1-15**, respectively.

1. Barry, F.P. (2003) "Biology and Clinical Applications of Mesenchymal Stem Cells." Birth Defect Research (Part C) 69:250-256; (**Exhibit 1**)
2. Chopp, M. and Li, Y. (2002) "Treatment of Neural Injury with Marrow Stromal Cells." The Lancet Neurology 1:92-100; (**Exhibit 2**)
3. Dennis JE, et al. (2002), "The STRO-1+ Marrow Cell Population is Multipotential." Cells Tissues Organs, 170:73-82; (**Exhibit 3**)
4. Greenberger, J. and Keating, A. (1996) "The Hematopoietic Microenvironment." Keystone Symposium, Taos, New Mexico 14:366-367; (**Exhibit 4**)
5. Hoerstrup SP et al. (2002), "Tissue Engineering of Functional Trileaflet Heart Valves From Human Marrow Stromal Cells." Circulation 106(Suppl):I-143-I-150; (**Exhibit 5**)
6. Kassem, M. (2004) "Mesenchymal Stem Cells: Biological Characteristics and Potential Clinical Applications." Cloning Stem Cells 6:369-374; (**Exhibit 6**)

7. Le Blanc, K. and Ringden, O. (2005) "Immunobiology of Human Mesenchymal Stem Cells and Future Use in Hematopoietic Stem Cell Transportation." Biology of Blood and Marrow Transplantation 11:321-334; **(Exhibit 7)**
8. Murray et al. (1996) "Fetal Bone Marrow CD34<sup>+</sup>CD41<sup>+</sup> Cells are Enriched for Multipotent Hematopoietic Progenitors, but not for Pluripotent Stem Cells." Exp. Hematol. 24:236-245; **(Exhibit 8)**
9. Summer, R. and Fine, A. (2008) "Mesenchymal Progenitor Limitations and Recommendations." Proc.Am, Thorac. Soc 5:707-710; **(Exhibit 9)**
10. November 13, 2007 Restriction Requirement issued in connection with U.S. Serial No. 11/169,875; **(Exhibit 10)**
11. October 16, 2008 Office Action issued in connection with U.S. Serial No. 10/955,709; **(Exhibit 11)**
12. November 13, 2008 Office Action issued in connection with U.S. Serial No. 10/551,326; **(Exhibit 12)**
13. November 17, 2008 Office Action issued in connection with U.S. Serial No. 11/326,736; **(Exhibit 13)**
14. November 26, 2008 Office Action issued in connection with U.S. Serial No. 11/169,875; **(Exhibit 14)** and
15. Finney, M.R. et al. (2006) "Direct Comparison of Umbilical Cord Blood versus Bone Marrow-Derived Endothelial Precursor Cells in mediating Neovascularization in Response to Vascular Ischemia."

Applicants: Stan Gronthos et al.  
Serial No.: 10/551,162  
Filed: March 29, 2004  
Page 23

Biol. Blood and Marrow Transplant. 12:585-593; (**Exhibit 15**).

The Examiner is respectfully requested to make of record each item listed on Form PTO-1449 Substitute by initialing and dating the attached Form PTO-1449 Substitute, and returning a copy of the initialed and dated form to applicants' undersigned attorney.


This Supplemental Information Disclosure Statement is being submitted under 37 C.F.R. §1.97(c)(2). Accordingly, applicants enclose a check which included the amount of ONE HUNDRED AND EIGHTY DOLLARS (\$180.00) for filing this Supplemental Information Disclosure Statement.

Applicants: Stan Gronthos et al.  
Serial No.: 10/551,162  
Filed: March 29, 2004  
Page 24

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee, other than the enclosed total fee of \$735.00 (which includes \$180.00 for an Information Disclosure Statement and \$555.00 for a three-month extension of time for a small entity), is deemed necessary in connection with the filing of this Amendment and Supplemental Information Disclosure Statement. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.


Respectfully submitted,



John P. White  
Registration No. 28,678  
Attorney for Applicants  
Customer No. 23432  
Cooper & Dunham LLP  
30 Rockefeller Plaza  
New York, New York 10112  
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

MAIL STOP AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450



John P. White  
Reg. No. 28,678

3/12/09  
Date